Nephros, Inc. (NEPH) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2026
Loading P/E history...
NEPH Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Nephros, Inc. (NEPH) trades at a price-to-earnings ratio of 29.4x, with a stock price of $3.23 and trailing twelve-month earnings per share of $0.07.
The current P/E is 55% below its 5-year average of 65.7x. Over the past five years, NEPH's P/E has ranged from a low of 22.8x to a high of 216.2x, placing the current valuation at the 17th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, NEPH trades at a 32% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, NEPH trades roughly in line with the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NEPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NEPH P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 25.2Lowest | 0.69Best | -65% | |
| $4B | 30.8 | 3.53 | -16% | |
| $124B | 34.9 | - | -5% | |
| $13B | 71.8 | - | +1156%Best | |
| $23B | 32.6 | 6.29 | +0% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
NEPH Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $2.98 | $0.07 | 43.9x | -33% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $4.88 | $0.11 | 44.2x | -33% |
| FY2025 Q3 | $4.73 | $0.14 | 34.3x | -48% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $4.09 | $0.12 | 32.7x | -50% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $1.72 | $0.08 | 22.8x | -65% |
| FY2024 Q4 | $1.47 | $0.01 | 216.2x | +229% |
Average P/E for displayed period: 65.7x
See NEPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NEPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NEPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNEPH — Frequently Asked Questions
Quick answers to the most common questions about buying NEPH stock.
Is NEPH stock overvalued or undervalued?
NEPH trades at 29.4x P/E, below its 5-year average of 65.7x. At the 17th percentile of historical range, the stock is priced at a discount to its own history.
How does NEPH's valuation compare to peers?
Nephros, Inc. P/E of 29.4x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is NEPH's PEG ratio?
NEPH PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2026.